Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Cowen & Co. Downgrades PhaseBio Pharmaceuticals to Market Perform

Cowen & Co. Downgrades PhaseBio Pharmaceuticals to Market Perform

Cowen & Co. analyst Phil Nadeau downgrades PhaseBio Pharmaceuticals (NASDAQ:PHAS) from Outperform to Market Perform.

byBenzinga Newsdesk

October 24, 2022

1 minute read

Cowen & Co. analyst Phil Nadeau downgrades PhaseBio Pharmaceuticals (NASDAQ:PHAS) from Outperform to Market Perform.

Top 3 Materials Stocks That Are Preparing To Pump In Q2

By Lisa Levin

June 14, 8:45 AM

The most oversold stocks in the materials sector presents an opportunity to buy into undervalued companies.

AUMN

News

On Nov 9, Jerash Holdings Signed A Memorandum Of Understanding To Establish A Joint Venture Company With Busana Apparel Group; Joint Venture To Produce Garments For Busana S Retail Customers

By Benzinga Newsdesk

November 10, 9:26 AM

- Reuters

JRSH

John Oliver Joins Inverse Jim Cramer Craze, Says You’d Live ’50 Years’ After Cramer Predicts You’d Die ‘Tomorrow’

By Chris Katje

April 26, 2:39 PM

Talk show host John Oliver has shared commentary on Jim Cramer previously and held nothing back when discussing the CNBC host's past comments about cryptocurrency and FTX co-founder Sam Bankman-Fried.

FRC

Analyst Ratings

A Glimpse Into The Expert Outlook On Exact Sciences Through 5 Analysts

By Benzinga Insights

January 2, 4:00 PM

In the preceding three months, 5 analysts have released ratings for Exact Sciences (NASDAQ:EXAS), presenting a wide array…

EXAS

Cowen & Co. Downgrades PhaseBio Pharmaceuticals to Market Perform

Related Posts

Top 3 Materials Stocks That Are Preparing To Pump In Q2

On Nov 9, Jerash Holdings Signed A Memorandum Of Understanding To Establish A Joint Venture Company With Busana Apparel Group; Joint Venture To Produce Garments For Busana S Retail Customers

John Oliver Joins Inverse Jim Cramer Craze, Says You’d Live ’50 Years’ After Cramer Predicts You’d Die ‘Tomorrow’

A Glimpse Into The Expert Outlook On Exact Sciences Through 5 Analysts